drugset / Trial / NCT03069326
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
Phase 2
Active not recruiting
30 enrolled
Memorial Sloan Kettering Cancer Center
Celgene Corporation · collabIncyte Corporation · collabM.D. Anderson Cancer Center · collabYale University · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test any good and bad effects of the study drugs called ruxolitinib and thalidomide. Ruxolitinib and thalidomide could shrink the cancer, but it could also cause side effects.
Timeline
- Start
- 2017-02-27
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | — | Oral |
| Subject | Thalidomide | Other / unclassified | — | Oral |